INTRODUCTION

Psoriasis is a chronic inflammatory skin disease associated with increased atherothrombosis and cardiovascular risk profile. It is a hyperproliferative, cutaneous condition with the potential to lower levels of folate. This may result in hyperhomocysteinemia that represents an independent risk factor for atherosclerotic cardiovascular disease, stroke, peripheral arterial occlusive disease and venous thrombosis. Psoriasis is a chronic and recurrent inflammatory skin disease characterized by erythematous scaling plaques, affecting 1-5% of the general population. An association between psoriasis and cardiovascular morbidity and mortality has been reported. Furthermore, cardiovascular risk factors, such as dyslipidaemia, hypertension, oxidative stress, diabetes mellitus and metabolic syndrome are more prevalent among patients with psoriasis, increase their cardiovascular risk profile. Homocysteine is a sulphur-containing amino acid generated by the catabolism of methionine. It is largely catabolized by trans-sulphuration to cysteine but it may also be re-methylated to methionine. Vitamin B12, vitamin B6 and folate are important cofactors in its metabolism. Plasma homocysteine is now established as a clinical risk factor for coronary artery disease, as well as other arterial and venous occlusive diseases. Homocysteine is thought to have thrombophilic properties due to an oxidative stress damaging vascular endothelium. For this reason, hyperhomocysteinaemia may constitute an independent risk factor for cardiovascular disease. Since many studies have demonstrated the presence of an increased homocysteinaemia value in psoriatic patients and considering that psoriasis is a disease associated with increased atherothrombosis, the aim of this study is to investigate the relationship between hyperhomocysteinaemia and psoriasis. The association between homocysteine and the severity of psoriasis was also evaluated.

MATERIALS AND METHODS

This case control study was conducted in Malda Medical College and Hospital, a rural based medical college and
hospital in West Bengal (India). Forty patients as cases were selected for the study.

**Inclusion criteria**
The patients were selected with history of red and itchy plaques over the skin covered with silver colored scales. The skin lesions are remitting and relapsing in nature.

**Exclusion criteria**
Subjects with any chronic illness, cancer, hyperuricemia were not included in the study. Patients taking any medications like corticosteroids, methotrexate, and with history of smoking and alcoholism were also excluded from the study.

Disease’s severity and coverage were assessed according to the Psoriasis Area and Severity Index (PASI). PASI score was applied to assess the severity and coverage of chronic plaque psoriasis, and the determinations were carried out at the time of the first evaluation of the patients. The PASI assesses the redness, thickness and scale of the psoriasis lesions, on a scale from 0 (none) to 4 (severe) for each of these attributes. The percentage of skin covered by psoriasis is also scored on a scale from 0 (0%) to 6 (90-100%). This is done for each of the trunk; head, arms and legs, and the scores are weighted by the location of psoriasis.

The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional) and with the Helsinki Declaration of 1975, as revised in 1983.

**Principle of serum homocysteine assay**
Homocysteine assay is based on the measurement of co-substrate conversion product. Oxidized homocysteine from the sample is reduced to free homocysteine which then reacts with SAM to form methionine and SAH. SAH is assessed by coupled enzyme reactions wherein adenosine is formed. The adenosine formed is hydrolysed into inosine and ammonia which reacts with glutamate dehydrogenase with concomitant conversions of NADH to NAD+. The concentration of homocysteine is proportional to the amount of NADH converted to NAD+ and is measured as change in absorbance at 340 nm.

**RESULT**
Plasma homocysteine levels were significantly higher in patients with psoriasis than in controls (mean= 12.43 vs 7.38 umol/L; SD = 1.9 vs. 0.6; t = -17.9; P = <0.001) (Table 1, Figures 1 and 2).

Considering the correlation between hyperhomocysteinaemia and psoriasis severity assessed by PASI, it directly correlate with homocysteine (p value= <0.01, Correlation coefficient =0.748) (Table 2 and Figure 3).
DISCUSSION

Psoriasis is a common chronic and recurrent inflammatory skin disorder that has been associated with abnormal plasma lipid metabolism\(^\text{12}\) high frequency of cardiovascular events\(^\text{13}\) and alterations in the risk of thromboembolic events\(^\text{14}\). In the literature, there are several studies that investigated homocysteine plasma levels in psoriatic patients. Refsum et al. in 1989 reported a higher homocysteine plasma level and lower folic acid level in 13 psoriatic patients\(^\text{15}\). Kural et al. studied 30 psoriatic patients and 30 controls; they found higher homocysteine plasma levels. Malerba et al. reported higher homocysteine in 40 psoriatic patients compared to 30 controls.

Our study, carried out on 50 psoriatic patients and 50 controls, showed significantly high plasma homocysteine levels among the psoriatic group (Table 1, Figures 1 and 2). Data from the literature confirm our results; several studies have shown that the homocysteine plasmatic concentration in psoriatic patients is higher than in healthy controls however, the correlation we found between homocysteine serum levels and psoriasis severity measured by PASI score has hardly ever been reported in the literature. Few studies show a relationship between homocysteine blood levels and disease activity. Physicians must find a pharmacological treatment that reduces the plasmatic homocysteine levels, even when these are only moderately high; we know that folic acid, vitamin B6 and vitamin B12 are all involved in breaking down homocysteine in the blood. Therefore dietary supplementation with folic acid and vitamins B6 and B12 is recommended.

Treatment of hyperhomocysteinaemia may not only reduce atherosclerotic plaque areas, but also it may decrease the risk of ischemic heart disease, deep vein thrombosis and stroke.\(^\text{16}\) Based on their findings, the authors suggest that psoriatic patients should be treated by a global management taking into account cardiovascular risk factors.

CONCLUSION

Psoriatic patients showed significantly high plasma homocysteine and significant correlation with psoriasis severity assessed by PASI. Physicians must find a pharmacological treatment that reduces the plasmatic homocysteine levels, even when these are only moderately high treatment of hyperhomocysteinaemia may not only reduce atherosclerotic plaque areas, but also it may decrease the risk of ischemic heart disease, deep vein thrombosis and stroke.\(^\text{16}\) Based on their findings, the authors suggest that psoriatic patients should be treated by a global management taking into account cardiovascular risk factors.

Abbreviations

SAM - S adenosylmethionine
SAH - S adenosylhomocysteine

REFERENCES

Authors Contribution:
M.D - Concept and design of the study, manuscript preparation, statistically analyzed and interpreted, critical revision of the manuscript; I.D - Concept and design of the study, critical revision of manuscript and review of the study; S.S - reviewed the literature, helped in preparing first draft of manuscript, collected data; K.D - collected data, statistically analyzed and interpreted, helped in preparing first draft of manuscript.

Orcid ID:
Dr. Mousumi Das: http://orcid.org/0000-0002-6698-110X
Dr. Indranil Dawn: http://orcid.org/0000-0002-4152-8421
Dr. Susmita Sarkar: http://orcid.org/0000-0002-9352-7586
Dr. Kapildev Das: http://orcid.org/0000-0001-8358-2488

Source of Support: Nil, Conflict of Interest: None declared.